195 related articles for article (PubMed ID: 32879207)
41. Risk Factors for Cisplatin-Induced Nephrotoxicity: A Multicenter Retrospective Study.
Miyoshi T; Uoi M; Omura F; Tsumagari K; Maesaki S; Yokota C
Oncology; 2021; 99(2):105-113. PubMed ID: 32966986
[TBL] [Abstract][Full Text] [Related]
42. Protection against cisplatin-induced nephrotoxicity by recombinant human erythropoietin.
Yalcin S; Müftüoğlu S; Cetin E; Sarer B; Yildirim BA; Zeybek D; Orhan B
Med Oncol; 2003; 20(2):169-74. PubMed ID: 12835520
[TBL] [Abstract][Full Text] [Related]
43. Synergistic protective effect of
Abdel-Wahab WM; Moussa FI; Saad NA
Drug Des Devel Ther; 2017; 11():901-908. PubMed ID: 28356716
[TBL] [Abstract][Full Text] [Related]
44. Captopril for prevention of contrast-induced nephropathy in diabetic patients: a randomised study.
Gupta RK; Kapoor A; Tewari S; Sinha N; Sharma RK
Indian Heart J; 1999; 51(5):521-6. PubMed ID: 10721643
[TBL] [Abstract][Full Text] [Related]
45. Telmisartan ameliorates cisplatin-induced nephrotoxicity by inhibiting MAPK mediated inflammation and apoptosis.
Malik S; Suchal K; Gamad N; Dinda AK; Arya DS; Bhatia J
Eur J Pharmacol; 2015 Feb; 748():54-60. PubMed ID: 25510231
[TBL] [Abstract][Full Text] [Related]
46. Methylglyoxal and D-lactate in cisplatin-induced acute kidney injury: Investigation of the potential mechanism via fluorogenic derivatization liquid chromatography-tandem mass spectrometry (FD-LC-MS/MS) proteomic analysis.
Chen SM; Chen TH; Chang HT; Lin TY; Lin CY; Tsai PY; Imai K; Chen CM; Lee JA
PLoS One; 2020; 15(7):e0235849. PubMed ID: 32649695
[TBL] [Abstract][Full Text] [Related]
47. The renin-angiotensin system blockade does not prevent renal interstitial fibrosis induced by aristolochic acids.
Debelle FD; Nortier JL; Husson CP; De Prez EG; Vienne AR; Rombaut K; Salmon IJ; Deschodt-Lanckman MM; Vanherweghem JL
Kidney Int; 2004 Nov; 66(5):1815-25. PubMed ID: 15496152
[TBL] [Abstract][Full Text] [Related]
48. Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: a retrospective study.
Yoshida T; Niho S; Toda M; Goto K; Yoh K; Umemura S; Matsumoto S; Ohmatsu H; Ohe Y
Jpn J Clin Oncol; 2014 Apr; 44(4):346-54. PubMed ID: 24503028
[TBL] [Abstract][Full Text] [Related]
49. Kinin B1 receptor deficiency attenuates cisplatin-induced acute kidney injury by modulating immune cell migration.
Estrela GR; Wasinski F; Almeida DC; Amano MT; Castoldi A; Dias CC; Malheiros DM; Almeida SS; Paredes-Gamero EJ; Pesquero JB; Barros CC; Câmara NO; Araújo RC
J Mol Med (Berl); 2014 Apr; 92(4):399-409. PubMed ID: 24357263
[TBL] [Abstract][Full Text] [Related]
50. Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity.
Ibrahim MA; Ashour OM; Ibrahim YF; El-Bitar HI; Gomaa W; Abdel-Rahim SR
Pharmacol Res; 2009 Nov; 60(5):373-81. PubMed ID: 19467331
[TBL] [Abstract][Full Text] [Related]
51. Salubrinal, an eIF2α dephosphorylation inhibitor, enhances cisplatin-induced oxidative stress and nephrotoxicity in a mouse model.
Wu CT; Sheu ML; Tsai KS; Chiang CK; Liu SH
Free Radic Biol Med; 2011 Aug; 51(3):671-80. PubMed ID: 21616140
[TBL] [Abstract][Full Text] [Related]
52. Comparative nephroprotective effects of curcumin and etoricoxib against cisplatin-induced acute kidney injury in rats.
Abd El-Kader M; Taha RI
Acta Histochem; 2020 May; 122(4):151534. PubMed ID: 32151374
[TBL] [Abstract][Full Text] [Related]
53. Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study.
Ikemura K; Oshima K; Enokiya T; Okamoto A; Oda H; Mizuno T; Ishinaga H; Muraki Y; Iwamoto T; Takeuchi K; Katayama N; Okuda M
Cancer Chemother Pharmacol; 2017 May; 79(5):943-949. PubMed ID: 28364288
[TBL] [Abstract][Full Text] [Related]
54. The effects of 2,3-dimercapto-1-propanesulfonic acid (DMPS) and meso-2,3-dimercaptosuccinic acid (DMSA) on the nephrotoxicity in the mouse during repeated cisplatin (CDDP) treatments.
Yajima Y; Kawaguchi M; Yoshikawa M; Okubo M; Tsukagoshi E; Sato K; Katakura A
J Pharmacol Sci; 2017 Jun; 134(2):108-115. PubMed ID: 28648300
[TBL] [Abstract][Full Text] [Related]
55. Protective effect of aminoguanidine against nephrotoxicity induced by cisplatin in normal rats.
Mansour MA; Mostafa AM; Nagi MN; Khattab MM; Al-Shabanah OA
Comp Biochem Physiol C Toxicol Pharmacol; 2002 Jun; 132(2):123-8. PubMed ID: 12106889
[TBL] [Abstract][Full Text] [Related]
56. Galectin 3 inhibition attenuates renal injury progression in cisplatin-induced nephrotoxicity.
Li HY; Yang S; Li JC; Feng JX
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30455396
[TBL] [Abstract][Full Text] [Related]
57. The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice.
Hirose A; Sato E; Fujii H; Sun B; Nishioka H; Aruoma OI
Toxicol Appl Pharmacol; 2007 Jul; 222(2):152-8. PubMed ID: 17555784
[TBL] [Abstract][Full Text] [Related]
58. Lower Blood Pressure-Induced Renal Hypoperfusion Promotes Cisplatin-Induced Nephrotoxicity.
Mizuno T; Hayashi T; Shimabukuro Y; Murase M; Hayashi H; Ishikawa K; Takahashi K; Yuzawa Y; Yamada S; Nagamatsu T
Oncology; 2016; 90(6):313-20. PubMed ID: 27225867
[TBL] [Abstract][Full Text] [Related]
59. Reversal of cisplatin-induced carnitine deficiency and energy starvation by propionyl-L-carnitine in rat kidney tissues.
Aleisa AM; Al-Majed AA; Al-Yahya AA; Al-Rejaie SS; Bakheet SA; Al-Shabanah OA; Sayed-Ahmed MM
Clin Exp Pharmacol Physiol; 2007 Dec; 34(12):1252-9. PubMed ID: 17973863
[TBL] [Abstract][Full Text] [Related]
60. [Studies on protective effect of selenium on the nephrotoxicity of cis-diamminedichloroplatinum (CDDP) in mice].
Araya Y
Hokkaido Igaku Zasshi; 1990 May; 65(3):245-53. PubMed ID: 2165995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
